Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Original Article

Volume 9, Number 5, October 2019, pages 151-158


Sitagliptin Versus Ipragliflozin for Type 2 Diabetes in Clinical Practice

Tables

Table 1. Characteristics of the Patients Treated With Sitagliptin or Ipragliflozin
 
CharacteristicSitagliptin (ASSET-K) (n = 1,313)Ipragliflozin (ASSIGN-K) (n = 431)P value
New: 876New: 394
Switched: 437Switched: 37
Data are the n (%) or mean ± standard deviation. aP < 0.05 Student’s t-test; bP < 0.05 Chi-square test. BMI: body mass index; HbA1c: hemoglobin A1c; eGFR: estimated glomerular filtration rate; DPP4: dipeptidyl peptidase-4; GLP-1: glucagon-like peptide-1; SGLT2: sodium-glucose cotransporter-2.
Age (years)62.9 ± 11.555.5 ± 11.4< 0.001a
Male/female740/573219/2120.045b
Body weight (kg)64.7 ± 1499.6 ± 12.5< 0.001a
BMI (kg/m2)24.7 ± 4.429.4 ± 5.3< 0.001a
Smoker373 (28.4)280 (65)< 0.001b
Drinking alcohol445 (33.9)155 (36)0.432
Hemoglobin A1c (%)8.01 ± 1.158.04 ± 1.420.710
Duration of diabetes (years)12.1 ± 8.19.6 ± 7.4< 0.001a
Mean blood pressure (mm Hg)93.7 ± 10.197.3 ± 11.6< 0.001a
eGFR (mL/min/1.73 m2)82 ± 22.383.3 ± 21.20.298
Complications
  Cerebrovascular disease68 (5.2)19 (4.4)0.524
  Myocardial infarction/angina81 (6.2)25 (5.8)0.781
  Arteriosclerosis obliterans26 (2)9 (2.1)0.890
  Hypertension605 (46.1)247 (57.3)< 0.001b
  Dyslipidemia611 (46.5)282 (65.4)< 0.001b
Prescribing pattern
  Initial treatment181 (13.8)55 (12.8)
  Add-on695 (52.9)339 (78.7)< 0.001b
  Switching437 (33.3)37 (8.6)
Medications
  Sulfonylureas833 (63.4)133 (30.9)< 0.001b
  Biguanides608 (46.3)222 (51.5)0.061
  Thiazolidinediones293 (22.3)58 (13.5)< 0.001b
  Glinides25 (1.9)28 (6.5)< 0.001b
  Alpha-glucosidase inhibitors112 (8.5)41 (9.5)0.532
  DPP4 inhibitors1,313 (100)258 (59.9)< 0.001b
  GLP-1 analogues0 (0)6 (1.4)< 0.001b
  SGLT2 inhibitors0 (0)431 (100)< 0.001b
  Insulin0 (0)78 (18.1)< 0.001b

 

Table 2. Changes of HbA1c, BMI, Mean Blood Pressure, and eGFR
 
ItemSitagliptin (ASSET-K)Ipragliflozin (ASSIGN-K)DifferenceP value
NLS meanSENLS meanSELS meanSE
P values were adjusted by analysis of covariance for age, sex, baseline duration of diabetes, baseline mean BMI, baseline mean blood pressure, baseline eGFR, and baseline HbA1c. HbA1c: hemoglobin A1c; BMI: body mass index; eGFR: estimated glomerular filtration rate; LS: least squares; SE: standard error. *P < 0.05.
eGFR (mL/min/1.73 m2)
  Δ 4 weeks364-2.450.58340-3.570.601.120.890.209
  Δ 12 weeks364-2.840.58340-1.970.610.870.900.333
  Δ 24 weeks364-4.150.59340-1.880.612.280.910.012*
HbA1c (%)
  Δ 4 weeks719-0.340.02343-0.420.030.080.030.012*
  Δ 12 weeks719-0.680.03343-0.780.040.090.050.083
  Δ 24 weeks719-0.720.03343-0.820.040.090.050.089
BMI (kg/m2)
  Δ 4 weeks6530.000.02344-0.380.040.380.05< 0.001*
  Δ 12 weeks653-0.030.03344-0.650.050.620.06< 0.001*
  Δ 24 weeks653-0.100.04344-0.760.060.660.07< 0.001*
Mean blood pressure (mm Hg)
  Δ 4 weeks679-0.700.33340-3.360.482.660.62< 0.001*
  Δ 12 weeks679-1.670.34340-2.180.500.510.640.428
  Δ 24 weeks679-0.660.36340-2.500.531.840.680.007*

 

Table 3. Changes of HbA1c, BMI, Mean Blood Pressure, and eGFR (Excluding Switched Patients)
 
ItemSitagliptin (ASSET-K)Ipragliflozin (ASSIGN-K)DifferenceP value
NLS meanSENLS meanSELS meanSE
P values were adjusted by analysis of covariance for age, sex, baseline duration of diabetes, baseline mean BMI, baseline mean blood pressure, baseline eGFR, and baseline HbA1c. HbA1c: hemoglobin A1c; BMI: body mass index; eGFR: estimated glomerular filtration rate; LS: least squares; SE: standard error. *P < 0.05.
eGFR (mL/min/1.73 m2)
  Δ 4 weeks206-2.860.82309-3.860.651.001.100.367
  Δ 12 weeks206-4.070.78309-2.440.621.631.050.121
  Δ 24 weeks206-4.690.81309-2.500.652.191.100.047*
HbA1c (%)
  Δ 4 weeks452-0.380.02311-0.460.030.080.040.029*
  Δ 12 weeks452-0.810.04311-0.890.040.080.060.190
  Δ 24 weeks452-0.870.04311-0.930.050.060.060.327
BMI (kg/m2)
  Δ 4 weeks409-0.020.03312-0.370.030.340.04< 0.001*
  Δ 12 weeks409-0.040.04312-0.620.050.580.07< 0.001*
  Δ 24 weeks409-0.140.05312-0.730.060.590.09< 0.001*
Mean blood pressure (mm Hg)
  Δ 4 weeks426-0.580.42308-3.270.502.690.69< 0.001*
  Δ 12 weeks426-1.810.45308-2.380.540.580.740.434
  Δ 24 weeks426-1.060.47308-2.410.561.350.770.081